Policy & Regulation
Hoth Therapeutics receives approval to start next phase of BioLexa trial for patients suffering with Atopic Dermatitis
22 June 2022 -

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a US-based biopharmaceutical company, announced on Tuesday that it has received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to start the next phase of its BioLexa trial for patients suffering with Atopic Dermatitis.

The product is a patented, proprietary antimicrobial topical formulation being produced for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialised communities consisting of bacteria adhered to a surface (both biological and abiotic surfaces) and to other bacteria, and often with a protective extracellular matrix.

The BioLexa formulation is optimised to prevent Staphylococcal biofilm formation, keeping the bacteria in a more susceptible state to antimicrobial therapy. The company said that this novel mechanism of action has the potential to broadly treat clinical manifestations resulting from Staphylococcal biofilm formation.



Related Headlines